Peripheral Ulcerative Keratitis

Back

Background

Peripheral ulcerative keratitis (PUK), also known as peripheral corneal ulceration, is a potentially devastating disorder consisting of a crescent-shaped destructive inflammation at the margin of corneal stroma that is associated with an epithelial defect, presence of stromal inflammatory cells, and progressive stromal degradation and thinning. Commonly referred to as PUK, it can quickly produce progressive necrosis of the corneal stroma, leading to perforation and blindness.[1]

Pathophysiology

The peripheral cornea has distinct morphologic and immunologic characteristics that predispose it to inflammatory reactions. Unlike the avascular central cornea, the peripheral cornea is closer to limbal conjunctiva and derives part of its nutrient supply from the limbal capillary arcade, a source of immunocompetent cells, for example, macrophages, Langerhans cells, lymphocytes, and plasma cells.[2, 3] Any inflammatory stimulus in the peripheral cornea that is caused by invasion of microbial organisms (bacteria, virus, fungi, and parasites), immune complex deposition (in systemic immune diseases), trauma, malignancy, or dermatologic conditions may produce local and systemic immune responses, resulting in neutrophil recruitment and complement activation (both classic and alternative pathways) in both tissue and vessels.[2]

Activated complement components can increase vascular permeability and further generate chemotactic factors for neutrophils (eg, C3a, C5a). Neutrophils, in turn, infiltrate the peripheral cornea and release proteolytic and collagenolytic enzymes, reactive oxygen metabolites, and proinflammatory substances (eg, platelet-activating factor, leukotrienes, prostaglandins), causing dissolution and degradation of the corneal stroma.[4, 5] In addition, the inflamed limbal conjunctiva itself is capable of producing collagenase, which contributes to stromal degradation.[6]

Systemic diseases that may cause immune complex deposition at the peripheral cornea and PUK include such collagen vascular diseases as rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA; previously known as Wegener granulomatosis), polyarteritis nodosa (PAN), relapsing polychondritis (RP), and systemic lupus erythematosus (SLE). Infectious conditions, whether systemic (eg, hepatitis, syphilis) or local (eg, herpes simplex keratitis, fungal keratitis), and noninfectious local disorders (eg, Mooren ulcer, marginal keratitis) may also cause PUK.

In summary, the major pathophysiologic mechanism of PUK is a result of degradation and tissue necrosis of corneal stroma produced by degradative enzymes, which are released primarily by neutrophils attracted into the area by diverse stimuli.

Epidemiology

Frequency

United States

Peripheral ulcerative keratitis (PUK) is uncommon. RA has been reported as the most common collagen vascular disorder that causes PUK, accounting for 34% of noninfectious PUK.[6, 7, 8] PUK may be the initial manifestation of WG and PAN. PUK is rare in patients with RP; only 2 of 112 patients with RP were reported to develop PUK in a clinical review study.[9] PUK has also been reported to be associated with SLE, although this is uncommon.[3, 10] Mooren ulcer is a rare local autoimmune disease associated with PUK, with only 287 cases reported in the world literature, although some of these cases may have been the presenting manifestation of an occult systemic disease rather than true Mooren ulcer.[11]

Mortality/Morbidity

PUK produces great morbidity from the pain and resultant visual disability. It can be a harbinger of death if the underlying disease is not diagnosed and successfully treated.

Race

No good data are available on racial predilection for PUK.

Sex

Since PUK is more common in people with collagen vascular disorders (especially RA), it is more common in females than in males. However, PUK caused by Mooren ulcer is more common in males than in females.[11, 12]

Age

Age varies and is dependent on the associated systemic or local disorder.

History

Peripheral ulcerative keratitis (PUK) is frequently a manifestation of an occult systemic disease. Thus, a thorough systemic history is very important and should include chief complaint, characteristics of present illness, past medical history, family history, and a meticulous review of systems.[4]

Ocular symptoms vary, but nonspecific foreign body sensation with or without eye pain, tearing, photophobia, and reduced visual acuity are the most common symptoms for patients with PUK.

Loss of vision can occur quickly when PUK progresses.

PUK associated with RA, GPA, PAN, and RP is often linked with scleritis, and eye pain may be pronounced in these individuals.[4] PUK in patients with Mooren ulcer may also produce pain, although there is no scleral involvement.

Past medical history and review of systems helps to determine the possible underlying systemic diseases. RA, SLE, PAN, GPA, or RP may present with the following symptoms, which should be emphasized in the review of systems[12] :

Physical

Examination should be complete and include an overview of the head (including the nose, mouth, and external ear), trunk, joints, and extremities.[4] Skin lesions should also be noted.

A complete ophthalmic examination should be performed with special emphasis on the conjunctiva, sclera, and cornea. Anterior chamber, vitreous, and fundus examinations are also important.

Patients with PUK typically present with decreased visual acuity (secondary to induced irregular astigmatism), tearing, and eye irritation with or without pain of variable duration.[5]

Bilateral disease may be present in 21% of patients.[13]

Slit lamp examination reveals a crescent-shaped destructive lesion of the juxtalimbal corneal stroma associated with an epithelial defect, stromal yellow-white infiltrates composed of inflammatory cells, and varying degrees of corneal stromal thinning (minimal to full thickness) adjacent to the limbus.[6]

In severe cases, the peripheral cornea is progressively destroyed circumferentially, and the central corneal is also damaged.

PUK accompanied by necrotizing scleritis almost always indicates the presence of a potentially lethal systemic disease.[4]

The anterior chamber should be evaluated for depth and inflammation.

A posterior segment examination is typically indicated to help determine the underlying etiology.

Causes

The etiologies for developing peripheral ulcerative keratitis (PUK) are multiple and extensive. Connective tissue and vasculitic diseases are the major risk factors. Other disorders that can cause PUK include systemic and local infectious conditions, as well as local degenerative disorders. Although vitamin A deficiency is commonly associated with central corneal ulceration, it has also been reported to cause peripheral ulceration with or without bacterial infection of the ulcer.[14, 15]

The differential diagnosis of PUK is outlined below.[4]

Laboratory Studies

Laboratory tests used to evaluate peripheral ulcerative keratitis (PUK) should focus on the suspected systemic disease, as follows:[4]

Imaging Studies

Local

Anterior-segment optical coherence tomography (OCT) may be used to document baseline corneal thickness and to monitor for progressive thinning.[29]

Systemic

Chest radiography and sinus CT scanning may be used to rule out GPA, sarcoidosis, and tuberculosis.

Radiography of affected joints may be performed.

Procedures

Scraping and culture of the ulcer are recommended.

Conjunctival resection/biopsy may be helpful in removing the limbal source of collagenases and other factors causing progressive ulceration.

Histologic Findings

In Mooren ulcer, corneal thickening occurs at the margin of the ulcer where inflammatory cells have invaded the anterior stromal layers. However, the inflammation is nonspecific, and no etiologic agent can be identified. Necrosis of the involved epithelium and stroma is seen. PUK associated with connective tissue disease and PUK associated with mild infections sometimes may appear similarly. Signs of vasculitis in the adjacent conjunctiva may be seen.[30]

Medical Care

Local treatment of peripheral ulcerative keratitis (PUK) is aimed at preventing or reducing corneal damage. Systemic therapy is aimed at controlling the underlying disease. A goal is reepithelialization of the epithelial defect to halt progressive corneal ulceration.

Surgical care may be combined with adjunctive local therapy with topical 1% medroxyprogesterone (which inhibits collagenase synthesis) or topical 20% N -acetylcysteine (a competitive inhibitor of collagenase). Lubricating drops, gels, and ointments and antibiotic drops or ointments can be helpful in aiding reepithelialization.

Topical steroid use is not recommended and should be used with caution in the treatment of patients with PUK associated with systemic disease because it may aggravate corneal melt due to collagen synthesis inhibition. However, some physicians would recommend its use only if the extent of corneal involvement is less than two quadrants and/or if stromal thickness is more than 50%.[31]

Systemic collagenase inhibitors (tetracycline 250-mg tab qid or doxycycline 100-mg tab bid) may help slow the progression.

Some physicians recommend oral vitamin C given at 500 mg four times a day to facilitate corneal healing.[31]

There is limited experience in the use of topical cyclosporine[32] and topical tacrolimus.[33] Topical cyclosporine combined with lamellar keratoplasty (see Surgical Care) was noted to improve the healing rate in Mooren ulcer.[34] However, an underlying systemic vasculitis is not addressed with this route of treatment.

Many studies have documented that patients with PUK who have associated systemic diseases have recurrences following localized temporizing treatment unless they are given adequate systemic immunosuppressive therapy. To address the underlying problem, both systemic steroid and cytotoxic immunosuppressive medications have been used, alone or in combination, and are effective at controlling ocular and systemic inflammation. Immunosuppressive agents have been indicated for management of the following:

Cyclophosphamide is the drug of choice for almost all PUK associated with a connective tissue disorder. The intravenous route has been used with success in PUK associated with rheumatoid arthritis.[35] Methotrexate (MTX), azathioprine, cyclosporine A, and chlorambucil have been found to be effective.[8] High-dose oral prednisone may be started, while the chemotherapeutic agents take effect after 4-6 weeks. When local or systemic infectious causes are suspected, therapy must be aimed at eliminating the infectious organism using the appropriate antibiotic medications based on clinical presentation or culture.

The use of the tumor necrosis factor alpha (TNF-alpha) antagonist infliximab has been reported to be effective in rheumatoid arthritis-associated PUK cases refractory to the above conventional immunomodulatory therapy.[36, 37] For its use in treating PUK in Crohn disease, see Pham et al.[38] . Adalimumab, a human monoclonal antibody against tumor necrosis factor, has been used with success in combination with other immunosuppressives to treat RA-associated PUK.[39]

Rituximab, a chimeric monoclonal antibody directed against the CD20 protein found in B cells, has been used in treatment-resistant PUK in GPA[40] and RA[41] , and was noted to have the highest success rate in achieving steroid-free remission in GPA-associated PUK.[42]

Surgical Care

Tissue adhesives, such as cyanoacrylate glue, are recommended for use in impending perforation and perforation size smaller than 1-2 mm.[6] Adhesive application follows keratectomy and conjunctival resection to remove sources of collagenase, cytokines, and inflammatory cells from the ulcerated cornea, temporarily preventing further stromal loss.



View Image

Peripheral ulcerative keratitis in the right eye of a patient with rheumatoid arthritis. Cyanoacrylate glue has been placed.

Application of a bandage contact lens prevents discomfort and dislodging of the adhesive.[6]

Amniotic membrane transplantation has been used in the management of Mooren ulcer.[43] Amniotic membranes have properties that promote rapid healing and reduce inflammation by sequestering inflammatory cells infiltrating the ocular surface.[44, 45] However, they may have a limited role in treating eyes with severe ischemia (eg, rheumatoid arthritis).[46] .

In severe cases of peripheral ulcerative keratitis (PUK) associated with membranous endothelial exudation, anterior chamber washout may be combined with amniotic membrane transplantation.[47]

Tectonic procedures, including lamellar keratoplasty, penetrating keratoplasty, and corneoscleral patch grafts, are performed as needed to maintain the integrity of the globe when corneoscleral perforation is imminent or has occurred.

The corneoscleral rim of donor grafts have been used in partial lamellar keratoplasty and may be an alternative in areas where donor corneas are scarce.[48]

Visual results of corneal transplantation may be disappointing. However, corneal clarity may be maintained with good visual outcomes when accompanied by aggressive systemic anti-inflammatory therapy in selected patients.[13]

Consultations

Referral to an appropriate specialist may be necessary. In patients with connective tissue diseases, comanagement with a rheumatologist is necessary to address the systemic disease. Pulmonary, nephrology, cardiac, hematology, and infectious disease consults may be necessary depending on the patient's symptoms and laboratory findings. Regular consultation with an oncologist may be necessary for those patients who are receiving chemotherapy.

Activity

Decreased visual acuity and systemic disorders may be limiting factors.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Prednisone (Deltasone, Orasone, Meticorten)

Clinical Context:  A synthetic glucocorticoid steroid with nonspecific anti-inflammatory and immunosuppressive effects.

Class Summary

Have both anti-inflammatory (glucocorticoid) and salt-retaining (mineralocorticoid) properties. Glucocorticoids have profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.

Tacrolimus ointment (Protopic)

Clinical Context:  Macrolide antibiotic that shares many pharmacologic properties with cyclosporine, and is similar in effects but does not produce cytotoxicity. Tacrolimus suppresses cell-mediated immunity by inhibiting DNA translation of specific lymphokines and the expression of the interleukin-2 receptor on activated T cells.

Methotrexate (Folex PFS, Rheumatrex)

Clinical Context:  A folic acid analog. Acts on the enzyme dihydrofolate reductase, which catalyses the reduction of folate to tetrahydrofolate, a compound necessary for DNA synthesis. Actively replicating cells, such as the leukocyte, are affected and their functions suppressed.

Azathioprine (Imuran)

Clinical Context:  A purine nucleoside analog that is activated in the liver producing metabolites, which interfere with purine metabolism. T- and B-cell functions are suppressed.

Cyclosporin A (Sandimmune, Neoral, SangCyA)

Clinical Context:  An 11-amino acid cyclic peptide and a natural product of fungi. Cyclosporine acts on T-cell replication and activity.

Cyclophosphamide (Cytoxan)

Clinical Context:  Nitrogen mustard derivative, which affects cell replication by alkylating purines in DNA and RNA.

Chlorambucil (Leukeran)

Clinical Context:  Slow-acting nitrogen mustard derivative, which interferes with DNA replication, transcription, and nucleic acid function by alkylation.

Class Summary

Inhibit key factors that mediate immune response.

Infliximab (Remicade)

Clinical Context:  Chimeric IgG1k monoclonal antibody that neutralizes cytokine TNF-α and inhibits its binding to TNF-α receptor. Reduces infiltration of inflammatory cells and TNF-α production in inflamed areas. Used with methotrexate in patients who have had inadequate response to methotrexate monotherapy.

Rituximab (Rituxan)

Clinical Context:  It is a chimeric monoclonal antibody directed against the CD20 protein, which is found primarily on the surface of B cells.

Adalimumab (Humira)

Clinical Context:  A human monoclonal antibody against tumour necrosis factor (TNF).

Class Summary

These agents alter the immune response to diverse stimuli.

Further Outpatient Care

Continued, possibly lifelong, follow-up care of peripheral ulcerative keratitis (PUK) is necessary even after complete resolution since relapses may occur. Furthermore, many patients may require prolonged systemic steroid, nonsteroidal anti-inflammatory, and/or chemotherapeutic medications for the systemic disease despite a quiet eye.



View Image

Same patient as in previous image, 1 year posttreatment.

Complications

Ocular complications include corneal scarring and neovascularization with irregular astigmatism, corneal thinning and perforation, loss of vision, and even blindness.



View Image

Left eye of same patient as in previous images. Note the corneal thinning and scarring.

Prognosis

In patients with collagen vascular diseases, peripheral ulcerative keratitis (PUK) with necrotizing scleritis is associated with poor life expectancy because of the presence of subclinical systemic vasculitis.

Patient Education

Inform patients about both ocular and systemic components of the disease, treatment options, and possible complications. Emphasize lifelong follow-up care.

For excellent patient education resources, visit eMedicineHealth's Eye and Vision Center. Also, see eMedicineHealth's patient education article Corneal Ulcer.

What is peripheral ulcerative keratitis (PUK)?What is the pathophysiology of peripheral ulcerative keratitis (PUK)?What is the prevalence of peripheral ulcerative keratitis (PUK) in the US?What is the morbidity associated with peripheral ulcerative keratitis (PUK)?What are the racial predilections of peripheral ulcerative keratitis (PUK)?What are the sexual predilections of peripheral ulcerative keratitis (PUK)?Which age groups have the highest prevalence of peripheral ulcerative keratitis (PUK)?Which clinical history findings are characteristic of peripheral ulcerative keratitis (PUK)?What are the symptoms of underlying systemic disease in peripheral ulcerative keratitis (PUK)?Which physical findings are characteristic of peripheral ulcerative keratitis (PUK)?What causes peripheral ulcerative keratitis (PUK)?Which conditions are included in the differential diagnoses of peripheral ulcerative keratitis (PUK)?What are the differential diagnoses for Peripheral Ulcerative Keratitis?What is the role of lab tests in the workup of peripheral ulcerative keratitis (PUK)?What is the role of imaging studies in the workup of peripheral ulcerative keratitis (PUK)?What is the role of biopsy in the workup of peripheral ulcerative keratitis (PUK)?Which histologic findings are characteristic of peripheral ulcerative keratitis (PUK)?How is peripheral ulcerative keratitis (PUK) treated?What is the role of immunosuppressive drugs in the treatment of peripheral ulcerative keratitis (PUK)?What is the role of cyclophosphamide in the treatment of peripheral ulcerative keratitis (PUK)?What is the role of infliximab in the treatment of peripheral ulcerative keratitis (PUK)?What is the role of rituximab in the treatment of peripheral ulcerative keratitis (PUK)?What is the role of surgery in the treatment of peripheral ulcerative keratitis (PUK)?Which specialist consultations are beneficial to patients with peripheral ulcerative keratitis (PUK)?What are the goals of drug treatment for peripheral ulcerative keratitis (PUK)?Which medications in the drug class Disease modifying agents are used in the treatment of Peripheral Ulcerative Keratitis?Which medications in the drug class Immunosuppressant agents are used in the treatment of Peripheral Ulcerative Keratitis?Which medications in the drug class Systemic corticosteroids are used in the treatment of Peripheral Ulcerative Keratitis?What is included in the long-term monitoring of peripheral ulcerative keratitis (PUK)?What are the possible complications of peripheral ulcerative keratitis (PUK)?What is the prognosis of peripheral ulcerative keratitis (PUK)?What is included in patient education about peripheral ulcerative keratitis (PUK)?

Author

Ellen N Yu-Keh, MD, Consulting Staff, Department of Ophthalmology, St Luke's Medical Center, Quezon City, Philippines

Disclosure: Nothing to disclose.

Coauthor(s)

C Stephen Foster, MD, FACS, FACR, FAAO, FARVO, Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Founder and President, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Aldeyra Therapeutics (Lexington, MA); Bausch & Lomb Surgical, Inc (Rancho Cucamonga, CA); Eyegate Pharma (Waltham, MA); Novartis (Cambridge, MA); pSivida (Watertown, MA); Xoma (Berkeley, CA); Allakos (Redwood City, CA)<br/>Serve(d) as a speaker or a member of a speakers bureau for: Alcon (Geneva, Switzerland); Allergan (Dublin, Ireland); Mallinckrodt (Staines-upon-Thames, United Kingdom)<br/>Received research grant from: Alcon; Aldeyra Therapeutics; Allakos Pharmaceuticals; Allergan; Bausch & Lomb; Clearside Biomedical; Dompé pharmaceutical; Eyegate Pharma; Mallinckrodt pharmaceuticals; Novartis; pSivida; Santen; Aciont.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, AAO, OMIC, Avedro; Bio-Tissue; GSK, Kala, Novartis; Shire; Sun Ophthalmics; TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Avedro; Bio-Tissue; Shire<br/>Received income in an amount equal to or greater than $250 from: AAO, OMIC, Avedro; Bio-Tissue; GSK, Kala, Novartis; Shire; Sun Ophthalmics; TearLab.

Chief Editor

Andrew A Dahl, MD, FACS, Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Disclosure: Nothing to disclose.

Additional Contributors

Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Lijing Yao, MD, to the development and writing of this article.

References

  1. Mondino BJ. Inflammatory diseases of the peripheral cornea. Ophthalmology. 1988 Apr. 95(4):463-72. [View Abstract]
  2. Shiuey Y, Foster CS. Peripheral ulcerative keratitis and collagen vascular disease. Int Ophthalmol Clin. 1998 Winter. 38(1):21-32. [View Abstract]
  3. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999 Mar-Apr. 43(5):379-96. [View Abstract]
  4. Foster CS, Sainz de la Maza M. Immunological considerations of the sclera. Foster CS, ed. The Sclera. 1st ed. New York: Springer-Verlag; 1993:33-58.
  5. Gregory JK, Foster CS. Peripheral ulcerative keratitis in the collagen vascular diseases. Int Ophthalmol Clin. 1996 Winter. 36(1):21-30. [View Abstract]
  6. Eiferman RA, Carothers DJ, Yankeelov JA Jr. Peripheral rheumatoid ulceration and evidence for conjunctival collagenase production. Am J Ophthalmol. 1979 May. 87(5):703-9. [View Abstract]
  7. Brown SI, Grayson M. Marginal furrows. A characteristic corneal lesion of rheumatoid arthritis. Arch Ophthalmol. 1968 May. 79(5):563-7. [View Abstract]
  8. Tauber J, Sainz de la Maza M, Hoang-Xuan T, et al. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea. 1990 Jan. 9(1):66-73. [View Abstract]
  9. Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology. 1990 Jul. 97(7):892-8. [View Abstract]
  10. Watson PG, Hazelman BC. The Sclera and Systemic Disorders. Philadelphia: WB Saunders Co; 1976. 241.
  11. Sangwan VS, Zafirakis P, Foster CS. Mooren's ulcer: current concepts in management. Indian J Ophthalmol. 1997 Mar. 45(1):7-17. [View Abstract]
  12. Tabbara KF. Mooren's ulcer. Int Ophthalmol Clin. 1986 Winter. 26(4):91-8. [View Abstract]
  13. Knox Cartwright NE, Tole DM, Georgoudis P, Cook SD. Peripheral ulcerative keratitis and corneal melt: a 10-year single center review with historical comparison. Cornea. 2014 Jan. 33(1):27-31. [View Abstract]
  14. Mattern RM, Ding J. Keratitis with Kocuria palustris and Rothia mucilaginosa in Vitamin A Deficiency. Case Rep Ophthalmol. 2014 Jan. 5(1):72-7. [View Abstract]
  15. Lange AP, Moloney G, Sheldon CA, Sasaki S, Holland SP. Bilateral Corneal Ulceration Caused by Vitamin A Deficiency in Eosinophilic Gastroenteropathy. Case Report Ophthalmol. 2011 Sep. 2(3):302-306. [View Abstract]
  16. Papathanassiou M, Zampeli E, Kaplanoglou T, Theodossiadis P. Peripheral ulcerative keratitis in a patient with systemic-onset juvenile idiopathic arthritis. J Pediatr Ophthalmol Strabismus. 2010 Oct 21. 47 Online:e1-3. [View Abstract]
  17. Ji YS, Yoon KC. A rare case of peripheral ulcerative keratitis associated with Behçet's disease. Int Ophthalmol. 2014 Feb 4. [View Abstract]
  18. Imbernón-Moya A, Vargas-Laguna E, Aguilar A, Gallego MÁ, Vergara C, Nistal MF. Peripheral Ulcerative Keratitis with Pyoderma Gangrenosum. Case Rep Dermatol Med. 2015. 2015:949840. [View Abstract]
  19. Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM. Ipilimumab-induced Ocular and Orbital Inflammation-A Case Series and Review of the Literature. Ocul Immunol Inflamm. 2016 Apr. 24 (2):140-6. [View Abstract]
  20. Iovieno A, Anand S, Dart JK. Late-onset peripheral ulcerative sclerokeratitis associated with alkali chemical burn. Am J Ophthalmol. 2014 Dec. 158 (6):1305-1309.e4. [View Abstract]
  21. Papaconstantinou D, Georgopoulos G, Kalantzis G, Krassas A, Georgalas I. Peripheral ulcerative keratitis after trabeculectomy in a patient with rheumatoid arthritis. Cornea. 2009 Jan. 28(1):111-3. [View Abstract]
  22. Kiire CA, Srinivasan S, Inglis A. Peripheral ulcerative keratitis after cataract surgery in a patient with ocular cicatricial pemphigoid. Cornea. 2011 Oct. 30(10):1176-8. [View Abstract]
  23. Chawla B, Agarwal P, Tandon R, et al. Peripheral ulcerative keratitis with bilateral optic nerve involvement as an initial presentation of acute lymphocytic leukemia in an adult. Int Ophthalmol. 2007 Nov 16. [View Abstract]
  24. Morjaria R, Barge T, Mordant D, Elston J. Peripheral ulcerative keratitis as a complication of acute myeloid leukaemia. BMJ Case Rep. 2014 Oct 31. 2014:[View Abstract]
  25. Carson DA. Rheumatoid factor. Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 3rd ed. Philadelphia: WB Saunders Co; 1989. 664-679.
  26. Lüdemann G, Gross WL. Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol. 1987 Aug. 69(2):350-7. [View Abstract]
  27. Savage CO, Winearls CG, Jones S, et al. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet. 1987 Jun 20. 1(8547):1389-93. [View Abstract]
  28. Nolle B, Specks U, Ludemann J, et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med. 1989 Jul 1. 111(1):28-40. [View Abstract]
  29. Garg A, De Rojas J, Mathews P, Hazan A, Lin J, Trief D, et al. Using Anterior Segment Optical Coherence Tomography to Monitor Disease Progression in Peripheral Ulcerative Keratitis. Case Rep Ophthalmol Med. 2018. 2018:3705753. [View Abstract]
  30. Squirrell DM, Winfield J, Amos RS. Peripheral ulcerative keratitis 'corneal melt' and rheumatoid arthritis: a case series. Rheumatology (Oxford). 1999 Dec. 38(12):1245-8. [View Abstract]
  31. Sharma N, Sinha G, Shekhar H, Titiyal JS, Agarwal T, Chawla B, et al. Demographic profile, clinical features and outcome of peripheral ulcerative keratitis: a prospective study. Br J Ophthalmol. 2015 Nov. 99 (11):1503-8. [View Abstract]
  32. Liegner JT, Yee RW, Wild JH. Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990 May 15. 109(5):610-2. [View Abstract]
  33. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008 Jun. 115(6):988-992.e5. [View Abstract]
  34. Chen J, Xie H, Wang Z, et al. Mooren's ulcer in China: a study of clinical characteristics and treatment. Br J Ophthalmol. 2000 Nov. 84(11):1244-9. [View Abstract]
  35. Clewes AR, Dawson JK, Kaye S, et al. Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics. Ann Rheum Dis. 2005 Jun. 64(6):961-2. [View Abstract]
  36. Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea. 2005 Aug. 24(6):742-4. [View Abstract]
  37. Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol. 2006 Dec. 12(6):291-3. [View Abstract]
  38. Pham M, Chow CC, Badawi D, Tu EY. Use of infliximab in the treatment of peripheral ulcerative keratitis in Crohn disease. Am J Ophthalmol. 2011 Aug. 152(2):183-188.e2. [View Abstract]
  39. Korsten P, Bahlmann D, Patschan SA. Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy. Rheumatology (Oxford). 2017 Jul 1. 56 (7):1094. [View Abstract]
  40. Huerva V, Sanchez MC, Traveset A, Jurjo C, Ruiz A. Rituximab for peripheral ulcerative keratitis with wegener granulomatosis. Cornea. 2010 Jun. 29(6):708-10. [View Abstract]
  41. Albert M, Beltrán E, Martínez-Costa L. [Rituximab in rheumatoid arthritis-associated peripheral ulcerative keratitis]. Arch Soc Esp Oftalmol. 2011 Apr. 86(4):118-20. [View Abstract]
  42. Ebrahimiadib N, Modjtahedi BS, Roohipoor R, Anesi SD, Foster CS. Successful Treatment Strategies in Granulomatosis With Polyangiitis-Associated Peripheral Ulcerative Keratitis. Cornea. 2016 Nov. 35 (11):1459-1465. [View Abstract]
  43. Lambiase A, Sacchetti M, Sgrulletta R, et al. Amniotic membrane transplantation associated with conjunctival peritomy in the management of Mooren's ulcer: a case report. Eur J Ophthalmol. 2005 Mar-Apr. 15(2):274-6. [View Abstract]
  44. Prabhasawat P, Tesavibul N, Komolsuradej W. Single and multilayer amniotic membrane transplantation for persistent corneal epithelial defect with and without stromal thinning and perforation. Br J Ophthalmol. 2001 Dec. 85(12):1455-63. [View Abstract]
  45. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders. Cornea. 2001 May. 20(4):408-13. [View Abstract]
  46. Tseng SC. Amniotic membrane transplantation for persistent corneal epithelial defect. Br J Ophthalmol. 2001 Dec. 85(12):1400-1. [View Abstract]
  47. Jia Y, Gao H, Li S, Shi W. Combined anterior chamber washout, amniotic membrane transplantation, and topical use of corticosteroids for severe peripheral ulcerative keratitis. Cornea. 2014 Jun. 33 (6):559-64. [View Abstract]
  48. Gao H, Wang X, Echegaray JJ, Li S, Wang T, Shi W. Partial lamellar keratoplasty for peripheral corneal disease using a graft from the glycerin-preserved corneoscleral rim. Graefes Arch Clin Exp Ophthalmol. 2014 Jun. 252 (6):963-8. [View Abstract]
  49. Jia Y, Gao H, Li S, Shi W. Combined Anterior Chamber Washout, Amniotic Membrane Transplantation, and Topical Use of Corticosteroids for Severe Peripheral Ulcerative Keratitis. Cornea. 2014 Apr 23. [View Abstract]
  50. Bullen CL, Liesegang TJ, McDonald TJ, et al. Ocular complications of Wegener's granulomatosis. Ophthalmology. 1983 Mar. 90(3):279-90. [View Abstract]
  51. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984 Oct. 91(10):1253-63. [View Abstract]
  52. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000 Oct. 130(4):492-513. [View Abstract]
  53. Robin JB, Schanzlin DJ, Verity SM, et al. Peripheral corneal disorders. Surv Ophthalmol. 1986 Jul-Aug. 31(1):1-36. [View Abstract]
  54. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976 Mar. 60(3):163-91. [View Abstract]

Peripheral ulcerative keratitis in the right eye of a patient with rheumatoid arthritis. Cyanoacrylate glue has been placed.

Same patient as in previous image, 1 year posttreatment.

Left eye of same patient as in previous images. Note the corneal thinning and scarring.

Peripheral ulcerative keratitis in the right eye of a patient with rheumatoid arthritis. Cyanoacrylate glue has been placed.

Same patient as in previous image, 1 year posttreatment.

Left eye of same patient as in previous images. Note the corneal thinning and scarring.